BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, Zaer-rezaii H, Amini-Kafiabad S, Maghsudlu M, Pourshams A, Malekzadeh R, Esmaili S. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 2010;14 Suppl 3:e113-6. [PMID: 20362479 DOI: 10.1016/j.ijid.2009.11.032] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Bastani MN, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M, Garshasebi S, Fakhim S. Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol. 2016;161:1899-1906. [PMID: 27132015 DOI: 10.1007/s00705-016-2862-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
2 Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci Rep. 2018;8:150. [PMID: 29317673 DOI: 10.1038/s41598-017-18296-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
3 Kabir K, Hoseini H, Miri M, Amrollahi F, Bahraini E, Afrogh P, Kalantar E. Prevalence of chronic viral hepatitis infections in Karaj, Iran. Pan Afr Med J 2017;28:186. [PMID: 29599884 DOI: 10.11604/pamj.2017.28.186.10269] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
5 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015; 7(12): 1708-1717 [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
6 Ashtari S, Vahedi M, Pourhoseingholi MA, Karkhane M, Kimiia Z, Pourhoseingholi A, Safaee A, Moghimi-Dehkordi B, Zali MR, Alavian SM. Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon. 2013;13:e8415. [PMID: 23930132 DOI: 10.5812/hepatmon.8415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
7 Alavian SM. Sofosbuvir has come out of the magic box. Hepat Mon 2013;13:e16916. [PMID: 24358046 DOI: 10.5812/hepatmon.16916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
8 Nematollahi S, Ayubi E, Almasi-Hashiani A, Mansori K, Moradi Y, Veisani Y, Jenabi E, Gholamaliei B, Khazaei S. Prevalence of hepatitis C virus infection among high-risk groups in Iran: a systematic review and meta-analysis. Public Health 2018;161:90-8. [PMID: 29935474 DOI: 10.1016/j.puhe.2018.04.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rezaee N, Babaeekhou L, Ghane M. Hepatitis C virus in Iran; transmission routes, growth in 3a genotype distribution, and lack of liver marker relation with genotypes. J Res Med Sci 2020;25:96. [PMID: 33273941 DOI: 10.4103/jrms.JRMS_482_19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ahmadi-Ghezeldasht S, Badiei Z, Sima HR, Hedayati-Moghaddam MR, Habibi M, Khamooshi M, Azimi A. Distribution of Hepatitis C Virus Genotypes in Patients with Major β-Thalassemia in Mashhad, Northeast Iran. Middle East J Dig Dis 2018;10:35-9. [PMID: 29682246 DOI: 10.15171/mejdd.2017.88] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Samimi-rad K, Sadeghi F, Amirzargar A, Eshraghian MR, Alavian S, Rahimnia R. Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran: HLA Class II and HCV Infection Outcome. J Med Virol 2015;87:1565-72. [DOI: 10.1002/jmv.24211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
12 Merat S, Sharifi AH, Haj-sheykholeslami A, Poustchi H, Fattahi B, Nateghi-baygi A, Alavian SM, Malekzadeh R. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3. Hepat Mon 2016;17. [DOI: 10.5812/hepatmon.44564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ravi S, Nasiri Toosi M, Karimzadeh I, Ahadi-Barzoki M, Khalili H. Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran. Hepat Mon 2013;13:e11038. [PMID: 24032043 DOI: 10.5812/hepatmon.11038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
14 Khorrami S, Mohammadpour H, Shahzamani K, Zarif MN, Sharifi AH, Merat S, Poustchi H. The relationship between HLA-G and viral loads in non-responder HCV-infected patients after combined therapy with IFN-α2α and ribavirin. Hum Immunol 2015;76:181-6. [PMID: 25500249 DOI: 10.1016/j.humimm.2014.12.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
15 Keshvari M, Sharafi H, Alavian SM, Mehrabadi H, Zolfaghari S. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. Transfus Apher Sci 2015;53:38-47. [PMID: 25892591 DOI: 10.1016/j.transci.2015.03.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
16 Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 2015; 21(38): 10790-10810 [PMID: 26478671 DOI: 10.3748/wjg.v21.i38.10790] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
17 Sepanlou SG, Etemadi A, Kamangar F, Sepehr A, Pourshams A, Poustchi H, Islami F, Sadjadi A, Nasrollahzadeh D, Semnani S, Saidi F, Abnet CC, Ponder B, Pharoah PD, Day NE, Brennan P, Boffetta P, Dawsey SM, Malekzadeh R. The gastro-esophageal malignancies in Northern Iran research project: impact on the health research and health care systems in Iran. Arch Iran Med 2013;16:46-53. [PMID: 23273237 DOI: 013161/AIM.0014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H. Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 2013;85:235-40. [PMID: 23168913 DOI: 10.1002/jmv.23460] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
19 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 692] [Cited by in F6Publishing: 617] [Article Influence: 76.9] [Reference Citation Analysis]
20 Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study. Hepat Mon 2012;12:e6618. [PMID: 23087764 DOI: 10.5812/hepatmon.6618] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
21 Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon. 2016;16:e37234. [PMID: 27642346 DOI: 10.5812/hepatmon.37234] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
22 Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, Merat S, Malekzadeh R. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One 2011;6:e23830. [PMID: 21887326 DOI: 10.1371/journal.pone.0023830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
23 Sharafi H, Poustchi H, Azimian F, Tamadoni B, Ramezani R, Gouya MM, Sheikh M, Hashemi F, Tashakorian M, Alasvand R, Alavian SM, Merat S. Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting. J Clin Virol 2019;113:20-3. [PMID: 30825832 DOI: 10.1016/j.jcv.2019.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
24 Huang H, Hu XF, Zhao FH, Garland SM, Bhatla N, Qiao YL. Estimation of Cancer Burden Attributable to Infection in Asia. J Epidemiol 2015;25:626-38. [PMID: 26399446 DOI: 10.2188/jea.JE20140215] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
25 Vosoghinia H, Esmaeilzadeh A, Ganji A, Hosseini SM, Jamehdar SA, Salehi M, Bahari A, Ghanaei O, Sahebari M, Rajabzadeh F, Ghaffarzadehgan K, Goshayeshi L. Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial. Razavi Int J Med 2016;4. [DOI: 10.17795/rijm36632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Khadempour-Arani H, Shojaeian A, Mehri-Ghahfarrokhi A, Shahraki HR, Karimi A, Dehghan A, Mobini GR. Identifying genotype profile of chronic hepatitis C infection in Southwest Iran. J Res Med Sci 2020;25:85. [PMID: 33273930 DOI: 10.4103/jrms.JRMS_524_19] [Reference Citation Analysis]
27 Lotfi AA, Mohamed AE, Shalaby NA, Eissa DS, El-Dabaa E, Sallam AM, Kamel MM, Abdelaziz H, El-Afifi AM, Abdel-Moneim AS. Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders. Int J Immunopathol Pharmacol 2020;34:2058738420961202. [PMID: 33045856 DOI: 10.1177/2058738420961202] [Reference Citation Analysis]
28 Moezzi M, Imani R, Karimi A, Pourheidar B. Hepatitis C Seroprevalence and Risk Factors in Adult Population of Chaharmahal and Bakhtiari Province of Iran in 2013. J Clin Diagn Res 2015;9:LC13-7. [PMID: 26557546 DOI: 10.7860/JCDR/2015/14986.6694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
29 Ghorbani NR, Djalalinia S, Modirian M, Abdar ZE, Mansourian M, Gorabi AM, Asayesh H, Ansari H, Atoofi MK, Tajbakhsh R, Noroozi M, Safiri S, Qorbani M. Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. J Res Med Sci 2017;22:123. [PMID: 29259634 DOI: 10.4103/jrms.JRMS_223_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Javanbakht M, Mirahmadizadeh A, Mashayekhi A. The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study. Iran Red Crescent Med J 2014;16:e13484. [PMID: 24719731 DOI: 10.5812/ircmj.13484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
31 Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, Salimi S, Hadian M. Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat Mon 2013;13:e12411. [PMID: 24069039 DOI: 10.5812/hepatmon.12411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
32 Mansour-ghanaei F, Mehrdad M, Mortazavi S, Joukar F, Khak M, Atrkar-roushan Z. Decreased serum total T3 level in hepatitis B and C related cirrhosis by severity of liver damage. Annals of Hepatology 2012;11:667-71. [DOI: 10.1016/s1665-2681(19)31440-1] [Cited by in Crossref: 19] [Article Influence: 1.9] [Reference Citation Analysis]
33 Khalsa JH, Mathur P. Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. Viruses 2021;13:1363. [PMID: 34372569 DOI: 10.3390/v13071363] [Reference Citation Analysis]
34 Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, Jamalidoust M, Hamidpour L. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon. 2013;13:e9147. [PMID: 24032048 DOI: 10.5812/hepatmon.9147] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
35 Pouri AA, Ghojazadeh M, Pourasghari B, Baiaz B, Soghra Hamzavi F, Somi MH. Seroepidemiology and risk factors of hepatitis C virus infection in East Azerbaijan, Iran: a population-based Azar Cohort study. Caspian J Intern Med 2019;10:326-31. [PMID: 31558996 DOI: 10.22088/cjim.10.3.326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Ravi S, Nasiri-toosi M, Karimzadeh I, Khalili H, Ahadi-barzoki M, Dashti-khavidaki S. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. Expert Opinion on Drug Safety 2014;13:277-86. [DOI: 10.1517/14740338.2014.866091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
37 Dehghani-dehej F, Sarvari J, Esghaei M, Hosseini SY, Garshasbi S, Kalantari S, Monavari SH, Fakhim A, Keyvani H, Bokharaei-salim F. Presence of different hepatitis C virus genotypes in plasma and peripheral blood mononuclear cell samples of Iranian patients with HIV infection. J Med Virol 2018;90:1343-51. [DOI: 10.1002/jmv.24925] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
38 Yahoo N, Sabahi F, Shahzamani K, Malboobi MA, Jabbari H, Sharifi H, Mousavi-fard SH, Merat S. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment. J Med Virol 2011;83:1332-7. [DOI: 10.1002/jmv.22144] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
39 Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894. [PMID: 23233864 DOI: 10.5812/hepatmon.6894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
40 Dehghani-dehej F, Hosseini Z, Mortazkar P, Khanaliha K, Esghaei M, Fakhim A, Bokharaei-salim F. Prevalence of HCV and/or HBV coinfection in Iranian HIV-infected patients. Future Virology 2020;15:155-63. [DOI: 10.2217/fvl-2019-0066] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H, Khoonsari M, Hemmasi G, Moradilakeh M, Motamed N, Maadi M. Prevalence and risk factors of hepatitis C virus infection in amol city, north of iran: a population-based study (2008-2011). Hepat Mon 2013;13:e13313. [PMID: 24358039 DOI: 10.5812/hepatmon.13313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
42 Behzadifar M, Behzadifar M, Bragazzi NL. A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran. BMC Public Health 2020;20:62. [PMID: 31937278 DOI: 10.1186/s12889-020-8175-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol 2017;206:165-74. [PMID: 28214926 DOI: 10.1007/s00430-017-0497-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
44 Bazi A, Mirimoghaddam E, Rostami D, Dabirzadeh M. Characteristics of Seropositive Hepatitis B and C Thalassemia Major Patients in South-East of Iran. Biotech Health Sci 2016;3. [DOI: 10.17795/bhs-35687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
45 Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani SS, Hesami-Zadeh K, Fakhim S. Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol. 2016;88:1960-1966. [PMID: 27463051 DOI: 10.1002/jmv.24474] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
46 Naghipour-khalkhaliani D, Behzadpour D, Mousavi Nasab SD. Distribution of Hepatitis C Virus Genotypes in Rasht, Capital City of Guilan Province, Northern Part of Iran. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Donyavi T, Bokharaei-Salim F, Khanaliha K, Sheikh M, Bastani MN, Moradi N, Babaei R, Habib Z, Fakhim A, Esghaei M. High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection. Arch Virol. 2019;164:2493-2504. [PMID: 31346769 DOI: 10.1007/s00705-019-04353-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
48 Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, Gheorghe L, El Hassan ES, Abaalkhail F, Abbas Z. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepat. 2015;22 Suppl 4:4-20. [PMID: 26513445 DOI: 10.1111/jvh.12475] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
49 Daw MA, El-Bouzedi AA, Ahmed MO, Dau AA, Agnan MM, Drah AM. Geographic integration of hepatitis C virus: A global threat. World J Virol 2016; 5(4): 170-182 [PMID: 27878104 DOI: 10.5501/wjv.v5.i4.170] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
50 Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HKF, Oluyemi AES. Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol. 2017;162:63-69. [PMID: 27665588 DOI: 10.1007/s00705-016-3049-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
51 Azarkeivan A, Toosi MN, Maghsudlu M, Kafiabad SA, Hajibeigi B, Hadizadeh M. The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: a fourteen-year study. Transfusion 2012;52:1814-8. [PMID: 22500658 DOI: 10.1111/j.1537-2995.2012.03652.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
52 Kasraian L, Imanieh MH, Tabrizi R, Shahriarirad R, Erfani A, Hosseini S. Prevalence of HBV and HCV Infections in Iranian Blood Donors; An Updated Systematic Review and Meta-Analysis. Middle East J Dig Dis 2021;13:237-52. [DOI: 10.34172/mejdd.2021.231] [Reference Citation Analysis]
53 Sheikh M, Bokharaei-Salim F, Monavari SH, Ataei-Pirkooh A, Esghaei M, Moradi N, Babaei R, Fakhim A, Keyvani H. Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users. Arch Virol. 2019;164:349-357. [PMID: 30390150 DOI: 10.1007/s00705-018-4066-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
54 Khazaei S, Karami M, Ayubi E, Mohammadbeigi A, Hasanbeigi A, Mansori K, Mir-Shekar MR. Trends in epidemiology of Hepatitis B and C Infections in Ilam Province: National Notifiable Diseases Surveillance System data. Caspian J Intern Med 2018;9:16-21. [PMID: 29387314 DOI: 10.22088/cjim.9.1.16] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Salari N, Kazeminia M, Hemati N, Ammari-Allahyari M, Mohammadi M, Shohaimi S. Global prevalence of hepatitis C in general population: A systematic review and meta-analysis. Travel Med Infect Dis 2022;46:102255. [PMID: 35007756 DOI: 10.1016/j.tmaid.2022.102255] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Muhamad NA, Ab Ghani RM, Abdul Mutalip MH, Muhammad EN, Mohamad Haris H, Mohd Zain R, Abdullah N, Muhammad Azami NA, Abd Jalal N, Ismail N, Mhd Yusuf NA, Othman R, Kamalul Arifin AS, Abdullah MS, Kamaruddin MA, Abu Hassan MR, Aris T, Jamal R. Seroprevalence of hepatitis B virus and hepatitis C virus infection among Malaysian population. Sci Rep 2020;10:21009. [PMID: 33273475 DOI: 10.1038/s41598-020-77813-5] [Reference Citation Analysis]
57 Merat S; SD1000 Research Team. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clin Infect Dis 2020;70:2206-12. [PMID: 31504303 DOI: 10.1093/cid/ciz628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
58 Samimi-Rad K, Asgari F, Nasiritoosi M, Esteghamati A, Azarkeyvan A, Eslami SM, Zamani F, Magnius L, Alavian SM, Norder H. Patient-to-Patient Transmission of Hepatitis C at Iranian Thalassemia Centers Shown by Genetic Characterization of Viral Strains. Hepat Mon 2013;13:e7699. [PMID: 23585766 DOI: 10.5812/hepatmon.7699] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
59 Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon 2013;13:e7991. [PMID: 23550108 DOI: 10.5812/hepatmon.7991] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
60 Nasimzadeh S, Azaran A, Jalilian S, Makvandi M, Seyedian SS, Keikhaei B, Mehr FJ. Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran. Arch Virol 2021;166:2703-10. [PMID: 34275067 DOI: 10.1007/s00705-021-05126-7] [Reference Citation Analysis]
61 Fattahi MR, Safarpour A, Sepehrimanesh M, Hosseini Asl SM, Mohamaddoust F. The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran. Hepat Mon 2015;15:e24734. [PMID: 25788957 DOI: 10.5812/hepatmon.24734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
62 Dehghan Manshadi SA, Merat S, Mohraz M, Rasoolinejad M, Sali S, Mardani M, Tabarsi P, Somi MH, Sedghi R, Tayeri K, Nikbin M, Karimi J, Sharifi AH, Kalantari S, Norouzi A, Merat D, Malekzadeh Z, Mirminachi B, Poustchi H, Malekzadeh R. Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus. Int J Clin Pract 2021;75:e14304. [PMID: 33930223 DOI: 10.1111/ijcp.14304] [Reference Citation Analysis]
63 Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M, Pourkarim MR. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. Infect Genet Evol 2019;75:103966. [PMID: 31323326 DOI: 10.1016/j.meegid.2019.103966] [Reference Citation Analysis]
64 Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20(29): 9633-9652 [PMID: 25110404 DOI: 10.3748/wjg.v20.i29.9633] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 95] [Article Influence: 13.3] [Reference Citation Analysis]
65 Eslamifar A, Ramezani A, Ehteram H, Razeghi E, Ahmadi F, Amini M, Banifazl M, Etemadi G, Keyvani H, Bavand A, Aghakhani A. Occult hepatitis C virus infection in Iranian hemodialysis patients. J Nephropathol. 2015;4:116-120. [PMID: 26457258 DOI: 10.12860/jnp.2015.22] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
66 Pouresmaeeli M, Alavian SM, Keshvari M, Salimi S, Mehrnoush L. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2015;15:e30780. [PMID: 26504470 DOI: 10.5812/hepatmon.30780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
67 Mahmud S, Kouyoumjian SP, Al Kanaani Z, Chemaitelly H, Abu-Raddad LJ. Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. Ann Epidemiol 2018;28:452-61. [PMID: 29661680 DOI: 10.1016/j.annepidem.2018.03.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
68 Mumtaz GR, Weiss HA, Vickerman P, Larke N, Abu-Raddad LJ. Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. AIDS 2015;29:1701-10. [PMID: 26372281 DOI: 10.1097/QAD.0000000000000761] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
69 Akbarzadeh Baghban A, Pourhoseingholi A, Zayeri F, Jafari AA, Alavian SM. Application of zero-inflated poisson mixed models in prognostic factors of hepatitis C. Biomed Res Int 2013;2013:403151. [PMID: 24195069 DOI: 10.1155/2013/403151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Musavi Z, Hashempour T, Moayedi J, Dehghani B, Ghassabi F, Hallaji M, Hosseini SY, Yaghoubi R, Gholami S, Dehyadegari MA, Merat S. Antibody Development to HCV Alternate Reading Frame Protein in Liver Transplant Candidate and its Computational Analysis. CP 2020;17:154-70. [DOI: 10.2174/1570164617666190822103329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
71 Li M, Wang ZQ, Zhang L, Zheng H, Zhou MG, Liu DW. Burden of viral hepatitis caused by specific aetiologies in China, 1990-2016: findings from the GBD 2016. BMC Public Health 2020;20:1461. [PMID: 32993585 DOI: 10.1186/s12889-020-09533-4] [Reference Citation Analysis]
72 Haj-sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol 2015; 21(29): 8935-8942 [PMID: 26269684 DOI: 10.3748/wjg.v21.i29.8935] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
73 Ziyaeyan M, Jamalidoust M, Moeini M. Evaluation of Hepatitis C Virus Infection in Antibody Positive Orphan Newborns. Jundishapur J Microbiol 2012;6:72-5. [DOI: 10.5812/jjm.4229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
74 Kahyesh-Esfandiary R, Sadigh ZA, Esghaei M, Bastani MN, Donyavi T, Najafi A, Fakhim A, Bokharaei-Salim F. Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: Occult HCV infection. J Med Virol. 2019;91:107-114. [PMID: 30091793 DOI: 10.1002/jmv.25279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, Semini I, Tawil O, Akala FA, Wilson D. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med. 2014;11:e1001663. [PMID: 24937136 DOI: 10.1371/journal.pmed.1001663] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 13.1] [Reference Citation Analysis]
76 Nassiri A, Dashti-khavidaki S, Khalili H, Nassiri-toosi M, Abdollahi A. Serum carnitine level and its associated factors in patients with chronic viral hepatitis. Future Virology 2014;9:373-83. [DOI: 10.2217/fvl.14.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Calise SJ, Chan EKL. Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery. Autoimmun Rev 2020;19:102643. [PMID: 32805424 DOI: 10.1016/j.autrev.2020.102643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
78 Mirminachi B, Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH, Poustchi H, Malekzadeh R. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.42291] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]